OUTLOOK THERAPEUTICS INC (OTLK) Stock Price & Overview
NASDAQ:OTLK • US69012T3059
Current stock price
The current stock price of OTLK is 0.219 USD. Today OTLK is up by 4.29%. In the past month the price decreased by -49.28%. In the past year, price decreased by -81.75%.
OTLK Key Statistics
- Market Cap
- 18.192M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.36
- Dividend Yield
- N/A
OTLK Stock Performance
OTLK Stock Chart
OTLK Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to OTLK. When comparing the yearly performance of all stocks, OTLK is a bad performer in the overall market: 98.43% of all stocks are doing better.
OTLK Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to OTLK. OTLK has a bad profitability rating. Also its financial health evaluation is rather negative.
OTLK Earnings
On February 17, 2026 OTLK reported an EPS of -0.22 and a revenue of -1.21M. The company missed EPS expectations (-19.83% surprise) and missed revenue expectations (-123.57% surprise).
OTLK Forecast & Estimates
10 analysts have analysed OTLK and the average price target is 3.95 USD. This implies a price increase of 1704.79% is expected in the next year compared to the current price of 0.219.
For the next year, analysts expect an EPS growth of -49.76% and a revenue growth 251.93% for OTLK
OTLK Groups
Sector & Classification
OTLK Financial Highlights
Over the last trailing twelve months OTLK reported a non-GAAP Earnings per Share(EPS) of -1.36. The EPS decreased by -51.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -563.97% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
OTLK Ownership
OTLK Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.07 | 369.265B | ||
| AMGN | AMGEN INC | 15.24 | 187.564B | ||
| GILD | GILEAD SCIENCES INC | 15.81 | 173.439B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.63 | 111.445B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.3 | 80.543B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.73 | 42.286B | ||
| INSM | INSMED INC | N/A | 35.012B | ||
| NTRA | NATERA INC | N/A | 29.477B | ||
| BIIB | BIOGEN INC | 11.03 | 26.026B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.91 | 24.756B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.643B | ||
| MRNA | MODERNA INC | N/A | 19.431B | ||
| INCY | INCYTE CORP | 12.53 | 19.091B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About OTLK
Company Profile
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Company Info
IPO: 2016-06-13
OUTLOOK THERAPEUTICS INC
111 S. Wood Avenue, Unit #100
Iselin NEW JERSEY 08852 US
CEO: Lawrence A. Kenyon
Employees: 17
Phone: 16096193990
OUTLOOK THERAPEUTICS INC / OTLK FAQ
What does OUTLOOK THERAPEUTICS INC do?
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. The company is headquartered in Iselin, New Jersey and currently employs 17 full-time employees. The company went IPO on 2016-06-13. The firm is focused on developing and commercializing ONS-5010/LYTENAVA (bevacizumab-gamma), an ophthalmic formulation of bevacizumab for use in retinal indications. The company is advancing ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO). Bevacizumab-vikg is a recombinant humanized monoclonal antibody (mAb) that selectively binds with high affinity to all isoforms of human vascular endothelial growth factor (VEGF) and neutralizes VEGF’s biologic activity through a steric blocking of the binding of VEGF to its receptors Flt-1 (VEGFR-1) and KDR (VEGFR-2) on the surface of endothelial cells. ONS-5010/LYTENAVA, consisted of three clinical trials which it refers to as NORSE ONE, NORSE TWO and NORSE THREE.
Can you provide the latest stock price for OUTLOOK THERAPEUTICS INC?
The current stock price of OTLK is 0.219 USD. The price increased by 4.29% in the last trading session.
What is the dividend status of OUTLOOK THERAPEUTICS INC?
OTLK does not pay a dividend.
What is the ChartMill rating of OUTLOOK THERAPEUTICS INC stock?
OTLK has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists OTLK stock?
OTLK stock is listed on the Nasdaq exchange.
Can you provide the short interest for OTLK stock?
The outstanding short interest for OUTLOOK THERAPEUTICS INC (OTLK) is 4.58% of its float.